Indication

Human Papillomavirus-16 Positive

1 clinical trial

1 product

Clinical trial

A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals

Status: Active (not recruiting), Estimated PCD: 2029-09-20

Product